Proper Name: Dengue Tetravalent Vaccine, Live
Manufacturer: Sanofi Pasteur Inc.
- Indicated for the prevention of dengue disease caused by dengue virus serotypes 1, 2, 3 and 4. DENGVAXIA is approved for use in individuals 9 through 16 years of age with laboratory-confirmed previous dengue infection and living in endemic areas.
- Package Insert - DENGVAXIA
- Demographic Subgroup Information – DENGVAXIA (Dengue Tetravalent Vaccine, Live)
Refer to Section 1.1 of the Clinical Review Memo for information about participation in the clinical trials and any analysis of demographic subgroup outcomes that is notable.